Pharsight

Nevanac generic

Nevanac is an anti-inflammatory drug owned by Novartis. The drug, which contains the active ingredient nepafenac, was first authorised for market use on 19 August, 2005. Nevanac is available in the form of suspension drops for ophthalmic use and has a total of 3 patents.

When will Nevanac generic be available?

As of now, Nevanac still has active patents that prevent the release of generic versions. The last patent held by Nevanac is set to expire on 31 January, 2027. After this date, it is possible for generics of Nevanac to be introduced to the market.

Nevanac uses

Nevanac is primarily used for the treatment of ocular inflammation. The active ingredient, nepafenac, plays a significant role in reducing swelling and pain in the eyes.

Nevanac patent expiration

Nevanac holds three patents, none of which have expired. The drug patents are titled 'Topical nepafenac formulations' which expire on different dates, the last one being on 31 January, 2027. Anticipation for the Nevanac generic version mounts as this date draws near. Below are the details of the patents:

Nevanac dosage

Want to ask something?